| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoarthritis, Knee | 169 | 2026 | 401 | 30.790 |
Why?
|
| Knee Joint | 107 | 2026 | 312 | 13.450 |
Why?
|
| Osteoarthritis | 63 | 2026 | 146 | 9.920 |
Why?
|
| Cartilage, Articular | 26 | 2024 | 79 | 6.540 |
Why?
|
| Disease Progression | 59 | 2026 | 1229 | 4.840 |
Why?
|
| Hand Joints | 11 | 2026 | 23 | 4.400 |
Why?
|
| Radiography | 69 | 2026 | 559 | 3.830 |
Why?
|
| Rheumatology | 10 | 2024 | 70 | 3.450 |
Why?
|
| Arthralgia | 18 | 2026 | 60 | 3.320 |
Why?
|
| Arthroplasty, Replacement, Knee | 11 | 2023 | 135 | 3.250 |
Why?
|
| Magnetic Resonance Imaging | 47 | 2024 | 2324 | 2.890 |
Why?
|
| Glucosamine | 22 | 2020 | 31 | 2.860 |
Why?
|
| Lupus Erythematosus, Systemic | 17 | 2025 | 185 | 2.800 |
Why?
|
| Middle Aged | 165 | 2026 | 18501 | 2.760 |
Why?
|
| Pain | 27 | 2024 | 400 | 2.690 |
Why?
|
| Humans | 285 | 2026 | 65843 | 2.610 |
Why?
|
| Glucocorticoids | 12 | 2023 | 190 | 2.600 |
Why?
|
| Injections, Intra-Articular | 27 | 2025 | 52 | 2.580 |
Why?
|
| Aged | 150 | 2026 | 15147 | 2.560 |
Why?
|
| Bone Marrow | 11 | 2020 | 178 | 2.540 |
Why?
|
| Osteoporosis | 7 | 2023 | 113 | 2.470 |
Why?
|
| Knee Injuries | 10 | 2023 | 49 | 2.420 |
Why?
|
| Synovitis | 8 | 2022 | 30 | 2.390 |
Why?
|
| Male | 180 | 2026 | 31410 | 2.360 |
Why?
|
| Tibia | 17 | 2023 | 76 | 2.340 |
Why?
|
| Female | 187 | 2026 | 34424 | 2.260 |
Why?
|
| Tai Ji | 8 | 2018 | 28 | 2.250 |
Why?
|
| Hyaluronic Acid | 13 | 2019 | 70 | 2.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 16 | 2023 | 202 | 2.150 |
Why?
|
| Bone Density | 13 | 2024 | 142 | 2.120 |
Why?
|
| Severity of Illness Index | 37 | 2026 | 1569 | 2.060 |
Why?
|
| Osteoarthritis, Hip | 9 | 2024 | 29 | 2.010 |
Why?
|
| Pain Measurement | 35 | 2025 | 344 | 2.010 |
Why?
|
| Antirheumatic Agents | 8 | 2018 | 227 | 1.950 |
Why?
|
| Practice Guidelines as Topic | 9 | 2024 | 741 | 1.920 |
Why?
|
| Viscosupplements | 6 | 2018 | 14 | 1.810 |
Why?
|
| Consensus | 10 | 2020 | 175 | 1.740 |
Why?
|
| Menisci, Tibial | 11 | 2024 | 29 | 1.740 |
Why?
|
| Adrenal Cortex Hormones | 7 | 2020 | 183 | 1.720 |
Why?
|
| Longitudinal Studies | 35 | 2024 | 1294 | 1.630 |
Why?
|
| Dietary Supplements | 13 | 2018 | 236 | 1.520 |
Why?
|
| Treatment Outcome | 40 | 2025 | 5834 | 1.490 |
Why?
|
| Vitamin D | 9 | 2020 | 139 | 1.430 |
Why?
|
| Cartilage | 5 | 2017 | 35 | 1.420 |
Why?
|
| Physical Therapy Modalities | 5 | 2020 | 46 | 1.360 |
Why?
|
| Tibial Meniscus Injuries | 6 | 2024 | 16 | 1.340 |
Why?
|
| Cartilage Diseases | 2 | 2022 | 12 | 1.310 |
Why?
|
| Hyaline Cartilage | 3 | 2016 | 4 | 1.270 |
Why?
|
| Knee | 8 | 2017 | 40 | 1.270 |
Why?
|
| Evidence-Based Medicine | 11 | 2024 | 464 | 1.260 |
Why?
|
| Patient Reported Outcome Measures | 9 | 2025 | 161 | 1.180 |
Why?
|
| Double-Blind Method | 15 | 2025 | 747 | 1.140 |
Why?
|
| Risk Factors | 52 | 2024 | 5475 | 1.140 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2020 | 811 | 1.110 |
Why?
|
| Rheumatic Diseases | 3 | 2021 | 42 | 1.010 |
Why?
|
| Arthritis, Rheumatoid | 6 | 2018 | 347 | 1.010 |
Why?
|
| Incidence | 22 | 2026 | 1433 | 0.980 |
Why?
|
| Fibromyalgia | 3 | 2018 | 15 | 0.980 |
Why?
|
| Case-Control Studies | 23 | 2026 | 1148 | 0.970 |
Why?
|
| Bone and Bones | 3 | 2016 | 152 | 0.930 |
Why?
|
| Follow-Up Studies | 22 | 2026 | 2500 | 0.920 |
Why?
|
| Vitamins | 3 | 2020 | 80 | 0.880 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2015 | 36 | 0.880 |
Why?
|
| Femur | 11 | 2023 | 56 | 0.860 |
Why?
|
| Carpometacarpal Joints | 2 | 2022 | 9 | 0.860 |
Why?
|
| Bone Malalignment | 2 | 2016 | 3 | 0.860 |
Why?
|
| Azithromycin | 1 | 2023 | 34 | 0.790 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 142 | 0.790 |
Why?
|
| Macrolides | 1 | 2023 | 38 | 0.790 |
Why?
|
| Exercise | 9 | 2025 | 970 | 0.780 |
Why?
|
| Bone Density Conservation Agents | 3 | 2017 | 45 | 0.760 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.750 |
Why?
|
| Cohort Studies | 26 | 2026 | 2651 | 0.750 |
Why?
|
| Chondroitin | 6 | 2015 | 9 | 0.740 |
Why?
|
| Cross-Sectional Studies | 27 | 2025 | 2739 | 0.740 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2021 | 169 | 0.730 |
Why?
|
| Sexual and Gender Minorities | 1 | 2024 | 76 | 0.730 |
Why?
|
| Internet | 7 | 2010 | 472 | 0.720 |
Why?
|
| United States | 28 | 2023 | 8189 | 0.710 |
Why?
|
| Chiroptera | 1 | 2022 | 17 | 0.710 |
Why?
|
| Joint Instability | 2 | 2019 | 57 | 0.700 |
Why?
|
| Machine Learning | 1 | 2024 | 197 | 0.700 |
Why?
|
| Arthritis | 2 | 2019 | 53 | 0.680 |
Why?
|
| Patient-Centered Care | 2 | 2014 | 268 | 0.660 |
Why?
|
| Time Factors | 16 | 2025 | 3779 | 0.660 |
Why?
|
| Prospective Studies | 22 | 2023 | 3340 | 0.630 |
Why?
|
| Walking | 6 | 2022 | 248 | 0.630 |
Why?
|
| Analgesics | 2 | 2019 | 102 | 0.620 |
Why?
|
| Overweight | 3 | 2020 | 254 | 0.620 |
Why?
|
| Body Mass Index | 16 | 2020 | 901 | 0.600 |
Why?
|
| Clinical Trials as Topic | 8 | 2018 | 462 | 0.600 |
Why?
|
| Vitamin D Deficiency | 3 | 2020 | 42 | 0.600 |
Why?
|
| Conservative Treatment | 1 | 2019 | 19 | 0.590 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2019 | 48 | 0.570 |
Why?
|
| Exercise Therapy | 4 | 2020 | 102 | 0.570 |
Why?
|
| Telomere Shortening | 1 | 2018 | 9 | 0.560 |
Why?
|
| Weight-Bearing | 6 | 2016 | 36 | 0.560 |
Why?
|
| Musculoskeletal Pain | 2 | 2015 | 27 | 0.550 |
Why?
|
| Quality of Life | 12 | 2025 | 1266 | 0.550 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2018 | 19 | 0.540 |
Why?
|
| Cancellous Bone | 1 | 2018 | 4 | 0.540 |
Why?
|
| Logistic Models | 13 | 2026 | 1274 | 0.540 |
Why?
|
| Diet | 6 | 2026 | 540 | 0.540 |
Why?
|
| Absorptiometry, Photon | 8 | 2018 | 76 | 0.540 |
Why?
|
| Leukocytes | 1 | 2018 | 110 | 0.540 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 57 | 0.520 |
Why?
|
| Biological Products | 2 | 2015 | 93 | 0.510 |
Why?
|
| Triamcinolone Acetonide | 1 | 2017 | 14 | 0.510 |
Why?
|
| Surveys and Questionnaires | 15 | 2024 | 2790 | 0.510 |
Why?
|
| Sodium Chloride | 1 | 2017 | 65 | 0.500 |
Why?
|
| Glycation End Products, Advanced | 1 | 2017 | 19 | 0.500 |
Why?
|
| Indazoles | 4 | 2022 | 19 | 0.500 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 36 | 0.500 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 170 | 0.500 |
Why?
|
| Meniscus | 1 | 2016 | 4 | 0.490 |
Why?
|
| Adult | 40 | 2025 | 17579 | 0.490 |
Why?
|
| Imidazoles | 4 | 2022 | 82 | 0.490 |
Why?
|
| Quadriceps Muscle | 1 | 2016 | 14 | 0.480 |
Why?
|
| Pyridines | 4 | 2022 | 120 | 0.470 |
Why?
|
| Algorithms | 4 | 2017 | 1060 | 0.470 |
Why?
|
| Mobile Applications | 3 | 2025 | 142 | 0.470 |
Why?
|
| Alcohol Drinking | 4 | 2022 | 325 | 0.470 |
Why?
|
| Weight Loss | 5 | 2024 | 276 | 0.460 |
Why?
|
| Estrogens | 2 | 2010 | 115 | 0.450 |
Why?
|
| Fluorocarbons | 2 | 2026 | 56 | 0.440 |
Why?
|
| Collagen | 2 | 2018 | 135 | 0.440 |
Why?
|
| Sex Characteristics | 1 | 2017 | 216 | 0.440 |
Why?
|
| Meta-Analysis as Topic | 4 | 2020 | 78 | 0.440 |
Why?
|
| Societies, Medical | 5 | 2019 | 401 | 0.430 |
Why?
|
| Age Factors | 11 | 2024 | 1595 | 0.430 |
Why?
|
| Finger Joint | 4 | 2024 | 13 | 0.430 |
Why?
|
| Single-Blind Method | 5 | 2018 | 142 | 0.430 |
Why?
|
| Body Weight | 1 | 2016 | 377 | 0.420 |
Why?
|
| Calcinosis | 2 | 2014 | 84 | 0.420 |
Why?
|
| Bone Marrow Diseases | 2 | 2011 | 14 | 0.420 |
Why?
|
| High-Energy Shock Waves | 1 | 2014 | 5 | 0.420 |
Why?
|
| Tendinopathy | 1 | 2014 | 11 | 0.420 |
Why?
|
| Prevalence | 11 | 2025 | 1454 | 0.410 |
Why?
|
| Rotator Cuff | 1 | 2014 | 15 | 0.410 |
Why?
|
| Range of Motion, Articular | 4 | 2018 | 116 | 0.410 |
Why?
|
| Linear Models | 6 | 2018 | 405 | 0.410 |
Why?
|
| Femur Neck | 2 | 2013 | 12 | 0.400 |
Why?
|
| Ultrasonography | 2 | 2013 | 491 | 0.400 |
Why?
|
| Prognosis | 7 | 2026 | 1793 | 0.390 |
Why?
|
| Polymorphism, Genetic | 3 | 2010 | 199 | 0.390 |
Why?
|
| Disease Management | 1 | 2015 | 235 | 0.390 |
Why?
|
| Complementary Therapies | 5 | 2013 | 63 | 0.380 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 1719 | 0.380 |
Why?
|
| Hydroxychloroquine | 1 | 2013 | 20 | 0.380 |
Why?
|
| Viscosupplementation | 1 | 2012 | 1 | 0.380 |
Why?
|
| Metacarpophalangeal Joint | 3 | 2023 | 10 | 0.380 |
Why?
|
| Pain Management | 3 | 2017 | 174 | 0.370 |
Why?
|
| Adjuvants, Immunologic | 2 | 2011 | 238 | 0.370 |
Why?
|
| Biomechanical Phenomena | 6 | 2020 | 296 | 0.360 |
Why?
|
| Aged, 80 and over | 26 | 2020 | 5682 | 0.350 |
Why?
|
| Musculoskeletal Diseases | 1 | 2012 | 105 | 0.350 |
Why?
|
| Sample Size | 4 | 2018 | 68 | 0.340 |
Why?
|
| Exercise Test | 1 | 2013 | 257 | 0.340 |
Why?
|
| Disability Evaluation | 6 | 2015 | 216 | 0.340 |
Why?
|
| Protein Hydrolysates | 1 | 2011 | 5 | 0.330 |
Why?
|
| Antioxidants | 3 | 2005 | 252 | 0.330 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2010 | 16 | 0.330 |
Why?
|
| Fractures, Bone | 3 | 2023 | 138 | 0.330 |
Why?
|
| Muscle Stretching Exercises | 1 | 2010 | 4 | 0.330 |
Why?
|
| Predictive Value of Tests | 9 | 2017 | 1117 | 0.320 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 84 | 0.320 |
Why?
|
| Kidney | 1 | 2013 | 460 | 0.320 |
Why?
|
| Walking Speed | 3 | 2020 | 24 | 0.320 |
Why?
|
| Aromatase | 1 | 2010 | 5 | 0.320 |
Why?
|
| Blood Glucose | 3 | 2017 | 502 | 0.310 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 24 | 0.310 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 49 | 0.310 |
Why?
|
| Semantics | 1 | 2010 | 58 | 0.300 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2022 | 22 | 0.300 |
Why?
|
| Patient Selection | 8 | 2020 | 484 | 0.290 |
Why?
|
| Lower Extremity | 2 | 2022 | 160 | 0.290 |
Why?
|
| Wnt Signaling Pathway | 3 | 2020 | 87 | 0.290 |
Why?
|
| Telemedicine | 4 | 2025 | 379 | 0.290 |
Why?
|
| Motor Activity | 4 | 2015 | 347 | 0.290 |
Why?
|
| Acetaminophen | 2 | 2022 | 53 | 0.290 |
Why?
|
| Gardening | 2 | 2025 | 4 | 0.290 |
Why?
|
| Acupuncture Analgesia | 1 | 2008 | 2 | 0.280 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2008 | 6 | 0.280 |
Why?
|
| Cosmetics | 1 | 2008 | 17 | 0.280 |
Why?
|
| Hand | 5 | 2024 | 79 | 0.270 |
Why?
|
| Obesity | 5 | 2020 | 1281 | 0.270 |
Why?
|
| Mouth, Edentulous | 1 | 2007 | 3 | 0.270 |
Why?
|
| Tooth Loss | 1 | 2007 | 8 | 0.270 |
Why?
|
| Retrospective Studies | 13 | 2025 | 6957 | 0.270 |
Why?
|
| Periodontal Diseases | 1 | 2007 | 17 | 0.270 |
Why?
|
| Diphosphonates | 2 | 2017 | 33 | 0.260 |
Why?
|
| Atmospheric Pressure | 1 | 2007 | 3 | 0.260 |
Why?
|
| Self Report | 4 | 2020 | 395 | 0.260 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 47 | 0.250 |
Why?
|
| Synovial Fluid | 2 | 2012 | 29 | 0.250 |
Why?
|
| Running | 2 | 2018 | 83 | 0.250 |
Why?
|
| Odds Ratio | 8 | 2020 | 757 | 0.250 |
Why?
|
| Risk Assessment | 6 | 2020 | 2116 | 0.240 |
Why?
|
| Caprylates | 1 | 2026 | 17 | 0.240 |
Why?
|
| Metabolome | 1 | 2026 | 39 | 0.230 |
Why?
|
| Nutritional Support | 1 | 2006 | 12 | 0.230 |
Why?
|
| Temperature | 1 | 2007 | 317 | 0.230 |
Why?
|
| Inflammation | 3 | 2024 | 1198 | 0.230 |
Why?
|
| Socioeconomic Factors | 9 | 2017 | 806 | 0.220 |
Why?
|
| Depression | 3 | 2021 | 910 | 0.220 |
Why?
|
| Smoking | 2 | 2015 | 864 | 0.220 |
Why?
|
| Thumb | 2 | 2022 | 27 | 0.220 |
Why?
|
| Fatigue | 1 | 2025 | 114 | 0.210 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2004 | 2 | 0.210 |
Why?
|
| Herpes Labialis | 1 | 2004 | 3 | 0.210 |
Why?
|
| Self-Management | 1 | 2025 | 72 | 0.210 |
Why?
|
| Biomarkers | 3 | 2026 | 1503 | 0.210 |
Why?
|
| Muscle, Skeletal | 3 | 2019 | 789 | 0.210 |
Why?
|
| Models, Theoretical | 2 | 2019 | 274 | 0.210 |
Why?
|
| Bicycling | 1 | 2024 | 20 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2018 | 888 | 0.200 |
Why?
|
| Interleukin-7 | 1 | 2024 | 30 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 256 | 0.200 |
Why?
|
| Resistance Training | 1 | 2023 | 23 | 0.200 |
Why?
|
| Minocycline | 1 | 2023 | 28 | 0.200 |
Why?
|
| Doxycycline | 1 | 2023 | 47 | 0.200 |
Why?
|
| Fibroblast Growth Factors | 1 | 2024 | 77 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 859 | 0.200 |
Why?
|
| Feasibility Studies | 4 | 2014 | 593 | 0.190 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2023 | 279 | 0.190 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 366 | 0.190 |
Why?
|
| Sex Factors | 8 | 2024 | 995 | 0.190 |
Why?
|
| Capsaicin | 1 | 2022 | 19 | 0.190 |
Why?
|
| Weight Gain | 1 | 2024 | 165 | 0.190 |
Why?
|
| Insulin | 1 | 2006 | 697 | 0.180 |
Why?
|
| Research Design | 4 | 2018 | 589 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 626 | 0.180 |
Why?
|
| Glucose | 3 | 2018 | 478 | 0.180 |
Why?
|
| Low Back Pain | 2 | 2020 | 113 | 0.180 |
Why?
|
| Genomics | 1 | 2025 | 387 | 0.180 |
Why?
|
| Patient Acuity | 1 | 2021 | 19 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 126 | 0.170 |
Why?
|
| Estrogen Antagonists | 1 | 2001 | 16 | 0.170 |
Why?
|
| Patient Compliance | 3 | 2010 | 370 | 0.170 |
Why?
|
| Europe | 2 | 2019 | 200 | 0.160 |
Why?
|
| Sulfonamides | 2 | 2015 | 135 | 0.160 |
Why?
|
| Chondrocytes | 3 | 2024 | 45 | 0.160 |
Why?
|
| Rheumatologists | 1 | 2020 | 7 | 0.160 |
Why?
|
| Child | 4 | 2023 | 4652 | 0.160 |
Why?
|
| Indoles | 1 | 2001 | 112 | 0.160 |
Why?
|
| Gout | 4 | 2006 | 48 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 1998 | 83 | 0.160 |
Why?
|
| Football | 1 | 2020 | 17 | 0.160 |
Why?
|
| Diet, Western | 1 | 2020 | 9 | 0.160 |
Why?
|
| Patella | 4 | 1996 | 13 | 0.150 |
Why?
|
| Swimming | 1 | 2019 | 30 | 0.150 |
Why?
|
| Chondromalacia Patellae | 1 | 1999 | 2 | 0.150 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2019 | 3 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 47 | 0.150 |
Why?
|
| Databases, Bibliographic | 2 | 2009 | 9 | 0.150 |
Why?
|
| Bayes Theorem | 2 | 2017 | 127 | 0.150 |
Why?
|
| Ligaments, Articular | 1 | 2019 | 20 | 0.150 |
Why?
|
| Ascorbic Acid | 2 | 1997 | 53 | 0.150 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2019 | 22 | 0.150 |
Why?
|
| Vitamin E | 2 | 1997 | 55 | 0.150 |
Why?
|
| Skin | 2 | 2017 | 436 | 0.150 |
Why?
|
| Synovial Membrane | 1 | 2019 | 21 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 198 | 0.150 |
Why?
|
| Physical Exertion | 1 | 1999 | 81 | 0.140 |
Why?
|
| Myelitis, Transverse | 1 | 2018 | 2 | 0.140 |
Why?
|
| Vitamin K | 1 | 2018 | 15 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 809 | 0.140 |
Why?
|
| Second Harmonic Generation Microscopy | 1 | 2018 | 1 | 0.140 |
Why?
|
| Neuromuscular Agents | 1 | 2018 | 16 | 0.140 |
Why?
|
| Telomere | 1 | 2018 | 59 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 296 | 0.140 |
Why?
|
| Luminescent Measurements | 1 | 2018 | 40 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 159 | 0.140 |
Why?
|
| Homeostasis | 2 | 2018 | 383 | 0.140 |
Why?
|
| Anxiety | 1 | 2021 | 427 | 0.130 |
Why?
|
| Sound | 1 | 2017 | 9 | 0.130 |
Why?
|
| Drug Approval | 1 | 2018 | 28 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2018 | 33 | 0.130 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 57 | 0.130 |
Why?
|
| Safety | 3 | 2004 | 142 | 0.130 |
Why?
|
| Denosumab | 1 | 2017 | 4 | 0.130 |
Why?
|
| Teriparatide | 1 | 2017 | 7 | 0.130 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2017 | 19 | 0.130 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 28 | 0.130 |
Why?
|
| Hip Joint | 2 | 2017 | 37 | 0.130 |
Why?
|
| Sulfates | 2 | 2007 | 14 | 0.130 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2017 | 4 | 0.130 |
Why?
|
| Clinical Protocols | 2 | 2015 | 138 | 0.130 |
Why?
|
| Spinal Cord | 1 | 2018 | 210 | 0.130 |
Why?
|
| Data Collection | 3 | 2015 | 384 | 0.120 |
Why?
|
| Dependovirus | 1 | 2024 | 760 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 301 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2024 | 852 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 2329 | 0.120 |
Why?
|
| Micronutrients | 1 | 1996 | 20 | 0.120 |
Why?
|
| Mindfulness | 1 | 2017 | 72 | 0.120 |
Why?
|
| Animals | 6 | 2024 | 21492 | 0.120 |
Why?
|
| Dietary Fats | 1 | 2017 | 181 | 0.120 |
Why?
|
| Optical Imaging | 1 | 2017 | 77 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 932 | 0.120 |
Why?
|
| Actigraphy | 1 | 2016 | 51 | 0.120 |
Why?
|
| Anthropometry | 1 | 2015 | 86 | 0.120 |
Why?
|
| Placebo Effect | 1 | 2015 | 10 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 746 | 0.110 |
Why?
|
| Carotenoids | 1 | 1996 | 68 | 0.110 |
Why?
|
| Observer Variation | 3 | 2014 | 217 | 0.110 |
Why?
|
| Naproxen | 1 | 2015 | 6 | 0.110 |
Why?
|
| Diclofenac | 1 | 2015 | 5 | 0.110 |
Why?
|
| Celecoxib | 1 | 2015 | 12 | 0.110 |
Why?
|
| Vitamin K 1 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Vitamin K Deficiency | 1 | 2014 | 3 | 0.110 |
Why?
|
| Ibuprofen | 1 | 2015 | 17 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2014 | 39 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 537 | 0.110 |
Why?
|
| Parathyroid Hormone | 1 | 2014 | 44 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 737 | 0.110 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 95 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2025 | 49 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2015 | 88 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2011 | 1030 | 0.100 |
Why?
|
| Shoulder Pain | 1 | 2014 | 16 | 0.100 |
Why?
|
| Women's Health | 2 | 2010 | 376 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2020 | 293 | 0.100 |
Why?
|
| Milk | 1 | 2014 | 47 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 1996 | 266 | 0.100 |
Why?
|
| Organ Size | 1 | 2014 | 175 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2014 | 41 | 0.100 |
Why?
|
| Arthritis, Infectious | 1 | 1993 | 20 | 0.100 |
Why?
|
| Nephritis | 1 | 1993 | 11 | 0.100 |
Why?
|
| Cadaver | 1 | 2014 | 135 | 0.100 |
Why?
|
| International Cooperation | 1 | 2014 | 87 | 0.100 |
Why?
|
| Hydrotherapy | 1 | 1993 | 2 | 0.100 |
Why?
|
| Patient Participation | 2 | 2020 | 239 | 0.100 |
Why?
|
| Cold Temperature | 1 | 1993 | 53 | 0.100 |
Why?
|
| Joints | 1 | 2013 | 33 | 0.100 |
Why?
|
| Fingers | 1 | 1993 | 49 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 190 | 0.090 |
Why?
|
| Abortion, Spontaneous | 2 | 2008 | 30 | 0.090 |
Why?
|
| Administration, Topical | 2 | 2020 | 51 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2017 | 149 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 122 | 0.090 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 149 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 312 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 618 | 0.090 |
Why?
|
| Chronic Pain | 1 | 2013 | 157 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 195 | 0.080 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 21 | 0.080 |
Why?
|
| Genotype | 2 | 2010 | 676 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2020 | 371 | 0.080 |
Why?
|
| Chondroitin Sulfates | 2 | 2020 | 11 | 0.080 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 85 | 0.080 |
Why?
|
| Giant Cell Arteritis | 1 | 1989 | 6 | 0.070 |
Why?
|
| Occipital Lobe | 1 | 1989 | 17 | 0.070 |
Why?
|
| Glucose Tolerance Test | 2 | 2006 | 97 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1989 | 28 | 0.070 |
Why?
|
| Adolescent | 5 | 2019 | 6368 | 0.070 |
Why?
|
| London | 3 | 2020 | 13 | 0.070 |
Why?
|
| Regression Analysis | 3 | 1996 | 498 | 0.070 |
Why?
|
| Health Behavior | 1 | 2012 | 485 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 375 | 0.070 |
Why?
|
| Cerebral Infarction | 1 | 1989 | 88 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 1663 | 0.070 |
Why?
|
| Psychology | 1 | 2008 | 45 | 0.070 |
Why?
|
| Temperance | 1 | 2008 | 13 | 0.070 |
Why?
|
| Control Groups | 1 | 2008 | 13 | 0.070 |
Why?
|
| Sex Distribution | 3 | 2012 | 252 | 0.070 |
Why?
|
| Drug Hypersensitivity | 1 | 2008 | 28 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2008 | 73 | 0.060 |
Why?
|
| Humidity | 1 | 2007 | 13 | 0.060 |
Why?
|
| Sleep | 1 | 2010 | 246 | 0.060 |
Why?
|
| Hazardous Waste | 1 | 2007 | 3 | 0.060 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 38 | 0.060 |
Why?
|
| Symptom Assessment | 2 | 2018 | 48 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 489 | 0.060 |
Why?
|
| ROC Curve | 2 | 2017 | 295 | 0.060 |
Why?
|
| Vasculitis | 1 | 2006 | 49 | 0.060 |
Why?
|
| Fasting | 1 | 2006 | 52 | 0.060 |
Why?
|
| Decanoic Acids | 1 | 2026 | 4 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 87 | 0.060 |
Why?
|
| Alkanesulfonic Acids | 1 | 2026 | 10 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 413 | 0.060 |
Why?
|
| Metabolomics | 1 | 2026 | 64 | 0.060 |
Why?
|
| Nutrition Assessment | 1 | 2005 | 28 | 0.060 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 90 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 312 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2025 | 27 | 0.060 |
Why?
|
| Phenotype | 2 | 2022 | 1236 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2007 | 228 | 0.050 |
Why?
|
| Neuroglia | 1 | 2025 | 81 | 0.050 |
Why?
|
| Metacarpal Bones | 1 | 2024 | 4 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2000 | 993 | 0.050 |
Why?
|
| Ointments | 1 | 2004 | 7 | 0.050 |
Why?
|
| Self Medication | 1 | 2004 | 13 | 0.050 |
Why?
|
| Proteome | 1 | 2025 | 153 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 119 | 0.050 |
Why?
|
| Urban Population | 1 | 2005 | 201 | 0.050 |
Why?
|
| Focus Groups | 1 | 2025 | 329 | 0.050 |
Why?
|
| Population Surveillance | 1 | 2005 | 210 | 0.050 |
Why?
|
| Whole Grains | 1 | 2023 | 2 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2003 | 38 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 294 | 0.050 |
Why?
|
| Medical Records | 1 | 2003 | 140 | 0.050 |
Why?
|
| Collagen Type II | 1 | 2002 | 12 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2002 | 10 | 0.040 |
Why?
|
| Receptors, Calcitriol | 1 | 2002 | 33 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 2002 | 97 | 0.040 |
Why?
|
| Fetomaternal Transfusion | 1 | 2001 | 1 | 0.040 |
Why?
|
| Arthrography | 2 | 2018 | 7 | 0.040 |
Why?
|
| Chimera | 1 | 2001 | 44 | 0.040 |
Why?
|
| Transcriptome | 1 | 2025 | 408 | 0.040 |
Why?
|
| Sensitivity and Specificity | 5 | 2005 | 1172 | 0.040 |
Why?
|
| Hydroxyestrones | 1 | 2001 | 4 | 0.040 |
Why?
|
| Reference Values | 2 | 2020 | 330 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2006 | 745 | 0.040 |
Why?
|
| Brazil | 1 | 2021 | 104 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2000 | 46 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2000 | 33 | 0.040 |
Why?
|
| Diffusion | 1 | 2000 | 83 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 2005 | 0.040 |
Why?
|
| Fructose | 2 | 1990 | 37 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 442 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 128 | 0.040 |
Why?
|
| Proprioception | 1 | 1999 | 9 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1999 | 22 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 197 | 0.040 |
Why?
|
| Syndrome | 1 | 1999 | 182 | 0.040 |
Why?
|
| Gait | 1 | 2020 | 124 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2018 | 1 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 1998 | 20 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 200 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1998 | 64 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1998 | 80 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 2018 | 20 | 0.030 |
Why?
|
| X-Rays | 1 | 2018 | 47 | 0.030 |
Why?
|
| Propensity Score | 1 | 2019 | 192 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1998 | 154 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1997 | 32 | 0.030 |
Why?
|
| Intervertebral Disc | 1 | 1997 | 21 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 4883 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 40 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1997 | 56 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 163 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2017 | 17 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2024 | 930 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 33 | 0.030 |
Why?
|
| Systole | 1 | 2017 | 109 | 0.030 |
Why?
|
| Physicians | 1 | 2003 | 488 | 0.030 |
Why?
|
| Hydroxycholecalciferols | 1 | 1996 | 1 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 389 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 430 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 391 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 691 | 0.030 |
Why?
|
| Chondrocalcinosis | 1 | 1996 | 3 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 122 | 0.030 |
Why?
|
| Monocytes | 1 | 1998 | 362 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 869 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2006 | 163 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 382 | 0.030 |
Why?
|
| Thyroid Diseases | 1 | 1996 | 28 | 0.030 |
Why?
|
| Leg | 1 | 2016 | 87 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2017 | 204 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 183 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2020 | 763 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1998 | 605 | 0.030 |
Why?
|
| Adiposity | 1 | 2016 | 89 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 62 | 0.030 |
Why?
|
| beta Carotene | 1 | 1996 | 67 | 0.030 |
Why?
|
| Accelerometry | 1 | 2016 | 64 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2006 | 225 | 0.030 |
Why?
|
| Mass Screening | 1 | 2001 | 700 | 0.030 |
Why?
|
| Republic of Korea | 1 | 2016 | 210 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 309 | 0.030 |
Why?
|
| Decarboxylation | 1 | 2014 | 1 | 0.030 |
Why?
|
| Osteophyte | 1 | 2014 | 5 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 319 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 3170 | 0.030 |
Why?
|
| Age Distribution | 3 | 2000 | 262 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 167 | 0.030 |
Why?
|
| Manipulation, Chiropractic | 1 | 2013 | 6 | 0.030 |
Why?
|
| West Indies | 1 | 1993 | 6 | 0.030 |
Why?
|
| Manipulation, Orthopedic | 1 | 2013 | 7 | 0.030 |
Why?
|
| Hip | 1 | 2013 | 7 | 0.020 |
Why?
|
| Ontario | 1 | 2013 | 58 | 0.020 |
Why?
|
| Gangrene | 1 | 1993 | 8 | 0.020 |
Why?
|
| Mutation | 1 | 2002 | 2674 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 318 | 0.020 |
Why?
|
| Social Class | 1 | 1993 | 137 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 375 | 0.020 |
Why?
|
| England | 1 | 1992 | 28 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 963 | 0.020 |
Why?
|
| Glucuronic Acid | 1 | 2012 | 20 | 0.020 |
Why?
|
| Hexuronic Acids | 1 | 2012 | 23 | 0.020 |
Why?
|
| Muscles | 1 | 1993 | 179 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1994 | 266 | 0.020 |
Why?
|
| Culture Media | 1 | 2012 | 78 | 0.020 |
Why?
|
| Alginates | 1 | 2012 | 50 | 0.020 |
Why?
|
| Pregnancy | 2 | 2001 | 2401 | 0.020 |
Why?
|
| Yttrium | 1 | 1990 | 7 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 1990 | 21 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1991 | 129 | 0.020 |
Why?
|
| Steroids | 1 | 1990 | 56 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2012 | 296 | 0.020 |
Why?
|
| Prednisolone | 1 | 1989 | 11 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 1989 | 7 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1989 | 37 | 0.020 |
Why?
|
| Health Status | 1 | 1992 | 448 | 0.020 |
Why?
|
| Liver | 2 | 1990 | 875 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 147 | 0.020 |
Why?
|
| Cefazolin | 1 | 2006 | 8 | 0.020 |
Why?
|
| Arterioles | 1 | 2006 | 8 | 0.020 |
Why?
|
| Aging | 1 | 2013 | 784 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 2006 | 7 | 0.020 |
Why?
|
| Boston | 1 | 2007 | 259 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2005 | 41 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 665 | 0.010 |
Why?
|
| Mice | 1 | 2018 | 11184 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 124 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 198 | 0.010 |
Why?
|
| Movement | 2 | 1994 | 166 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2001 | 77 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2001 | 161 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 2001 | 20 | 0.010 |
Why?
|
| Braces | 1 | 2000 | 10 | 0.010 |
Why?
|
| Shoes | 1 | 2000 | 13 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2002 | 297 | 0.010 |
Why?
|
| Acupuncture Therapy | 1 | 2000 | 18 | 0.010 |
Why?
|
| Bias | 1 | 2001 | 117 | 0.010 |
Why?
|
| Uric Acid | 2 | 1990 | 47 | 0.010 |
Why?
|
| Behavior Therapy | 1 | 2000 | 169 | 0.010 |
Why?
|
| Massachusetts | 1 | 2005 | 2158 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1998 | 63 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1998 | 29 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 1998 | 69 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1998 | 51 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1998 | 267 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1997 | 141 | 0.010 |
Why?
|
| Spine | 1 | 1996 | 55 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 1996 | 12 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1996 | 34 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 532 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 1997 | 178 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 1990 | 25 | 0.010 |
Why?
|
| Physical Examination | 1 | 1990 | 109 | 0.000 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1990 | 4 | 0.000 |
Why?
|
| Phosphates | 1 | 1990 | 104 | 0.000 |
Why?
|
| Purines | 1 | 1990 | 43 | 0.000 |
Why?
|
| Dietary Carbohydrates | 1 | 1990 | 62 | 0.000 |
Why?
|
| Heterozygote | 1 | 1990 | 175 | 0.000 |
Why?
|